Amicus Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell FOLD and other ETFs, options, and stocks.

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.

CEO

Bradley Lewis Campbell

CEOBradley Lewis Campbell

Employees

499

Employees499

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

2002

Founded2002

Employees

499

Employees499

FOLD Key Statistics

Market cap

3.27B

Market cap3.27B

Price-Earnings ratio

-236.02

Price-Earnings ratio-236.02

Dividend yield

—

Dividend yield—

Average volume

4.74M

Average volume4.74M

High today

$10.85

High today$10.85

Low today

$9.79

Low today$9.79

Open price

$9.92

Open price$9.92

Volume

12.05M

Volume12.05M

52 Week high

$11.00

52 Week high$11.00

52 Week low

$5.51

52 Week low$5.51

Stock Snapshot

As of today, Amicus Therapeutics(FOLD) shares are valued at $10.78. The company's market cap stands at 3.27B, with a P/E ratio of -236.02.

On 2025-12-12, Amicus Therapeutics(FOLD) stock moved within a range of $9.79 to $10.85. With shares now at $10.78, the stock is trading +10.1% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 12.05M, compared to an average daily volume of 4.74M.

Over the past 52 weeks, Amicus Therapeutics(FOLD) stock has traded between a high of $11.00 and a low of $5.51.

Analyst ratings

90%

of 10 ratings

Buy

90%

Hold

10%

Sell

People also own

Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.